A partnership between St. Jude and Mustang Bio may change the challenges faced by those diagnosed with what is commonly referred to as “bubble boy disease.” A partnership between St. Jude and Mustang ...
A gene therapy for a rare type of severe combined immunodeficiency (SCID) was safe and sufficiently restored T-cell immunity in an early trial, results from a phase I/II study showed. At a single ...
Several infants treated with autologous ex vivo gene therapy for newly diagnosed X-linked severe combined immunodeficiency (X-SCID) in a phase I/II trial have developed fully functioning immune ...
X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural killer (NK) cell function, caused by mutations in ...
The cytokine receptor common gamma chain (γc) is shared among the receptors for interleukin (IL)-2, -4, -7, -9, -15, and plays a pivotal role in transmitting these cytokine signals. 1,2 Many of these ...
New animal studies conducted at the Salk Institute for Biological Studies show that the only human gene therapy treatment to date considered to be largely successful, is, in fact, riskier than ...
Findings from St. Jude Children's Research Hospital demonstrate that virtual memory T cells, a specialized group of immune cells, provide nonspecific immunity for infants early in life. Patients with ...
A small clinical trial has shown that gene therapy can safely correct the immune systems of infants newly diagnosed with a rare, life-threatening inherited disorder in which infection-fighting immune ...
La Jolla, CA – New animal studies conducted at the Salk Institute for Biological Studies show that the only human gene therapy treatment to date considered to be largely successful, is, in fact, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results